Categories
Lung Cancer

✅ Passive Smoking/Secondhand Smoking in Lung Cancer #ICareForLungs | Dr. Arvind Kumar [Video]

✅ Passive Smoking/Secondhand Smoking in Lung Cancer #ICareForLungs | Dr. Arvind Kumar

Lung Cancer Awareness -: “ Passive smoking/ Secondhand smoking & lung cancer ”
#ICareForLungs

Have you ever thought about what will happen if your lungs stopped breathing for you?

In the current scenario, considering the lifestyle and the pollution, we don’t pay a lot of attention to the health of our lungs.

Today, greet your lungs with the gift of health and happiness by affirming #ICareForLungs.

#ICareForLungs is an awareness drive started by Prof. (Dr.) Arvind Kumar, a leading lung specialist of India, looking at the rising number of lung cancer cases across the country. Dr. Kumar took this initiative to make people aware of lung health and tips for healthy lung life.

This is the first-of-its-kind initiative taken by a doctor in India to create awareness about lung health on a global level and aims at creating awareness regarding lung cancer.

✅ Passive Smoking/Secondhand Smoking in Lung Cancer #ICareForLungs | Dr. Arvind Kumar

⏰ Save the time..
You may ask your questions in the comment section 👇 or through DMs. 💌

#instalive #livestreaming #streaming #LungCancerAwareness #DrArvindKumar #Lungcancercampaign #LungCancerAwarenessMonth #GiftForYourLungs #SwasthBharatSamarthBhar #Passivesmoking #passivesmokingkills #secondhandsmoking #smokinglover #smokingkills #Lungcancerfighter #Quitsmoking #Lungcancersurvivor #Respiratorycare #lungcancertreatment #lungcancerprevention

Watch/Read More
Categories
Lung Cancer

Oncotarget | Effects of Metformin and Rapamycin in Pancreatic Cancer [Video]

Oncotarget published this trending research paper on May 26, 2020, entitled, "An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma" by researchers from the Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; The Skip Viragh Center for Pancreas Cancer at Johns Hopkins, Baltimore, MD; Virginia Piper Cancer Center at HonorHealth, Scottsdale, AZ; Molecular Medicine Division, Translational Genomics Research Institute (TGen), Phoenix, AZ; Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Department of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai City, China; The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD.Abstract:Purpose: Metformin combined with the mTOR inhibitor rapamycin showed potential synergistic anti-tumor activity in preclinical studies in pancreatic ductal adenocarcinoma (PDA). This phase 1b study (NCT02048384) was conducted to evaluate the feasibility and activity of metformin +/– rapamycin in the maintenance setting for unselected patients with metastatic PDA (mPDA) treated with chemotherapy.Materials and Methods: Eligible patients with stable or responding mPDA after ≥ 6 months on chemotherapy were randomized 1:1 to metformin alone (Arm A) or with rapamycin (Arm B), stratified by prior treatment with FOLFIRINOX. Fluorodeoxyglucose (FDG) PET scans and peripheral blood mononuclear cells were obtained for exploratory analyses.Results: 22 subjects (11 per arm) received treatment per protocol. Median PFS/OS were 3.5 and 13.2 months respectively, with 2 year OS rate of 37%; there were no differences between arms. No responses were observed by RECIST; however, decreases in FDG avidity and/or CA19-9 were observed in several long-term survivors. Treatment related adverse events of Grade ≥ 3 occurred in 0% vs 27% of patients in Arm A vs B and were asymptomatic hematologic or electrolyte abnormalities that were not clinically significant. Improved survival was associated with low baseline neutrophil: lymphocyte ratio, baseline lack of assessable disease by PET, and greater expansion of dendritic cells following treatment.Conclusions: Metformin +/– rapamycin maintenance for mPDA was well-tolerated and several patients achieved stable disease associated with exceptionally long survival. Further prospective studies are needed to clarify the role of these agents in the maintenance setting and to enhance patient selection for such approaches.Press release - https://www.oncotarget.com/news/pr/an-exploratory-study-of-metformin-and-rapamycin-as-maintenance-therapy/Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27586DOI - https://doi.org/10.18632/oncotarget.27586Full text - https://www.oncotarget.com/article/27586/text/Correspondence to - Dung T. Le - dle@jhmi.edu Keywords - pancreatic cancer, mTOR inhibition, maintenance therapy, metformin, rapamycinAbout OncotargetOncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:SoundCloud - https://soundcloud.com/oncotargetFacebook - https://www.facebook.com/Oncotarget/Twitter - https://twitter.com/oncotargetInstagram - https://www.instagram.com/oncotargetjrnl/YouTube - https://www.youtube.com/c/OncotargetYouTube/LinkedIn - https://www.linkedin.com/company/oncotargetPinterest - https://www.pinterest.com/oncotarget/Reddit - https://www.reddit.com/user/Oncotarget/Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnlsMedia ContactMEDIA@IMPACTJOURNALS.COM18009220957

Categories
Lung Cancer

Oncology Nurse Hour: Non-Small Cell Lung Cancer [Video]

In this episode of Oncology Nurse Hour, we will discuss non-small cell lung cancer with expert oncology nurse Kristin Johnston. Topics that will be covered during this event include:What Is non-small cell lung cancer with MET alterations? How do alterations and mutations change the prognosis or lung cancer? What treatments target MET alterations? Genomic testing for non-small cell lung cancer Clinical trials for non-small cell lung cancer and MET alterations Massive Bio and our expert nurses and patient advocates will host the eleventh episode of our new webinar series: Oncology Nurse Hour. For this new, live, series, we take questions directly from the community and discuss all you could want to know about different cancer types, ending each session with a live Q&A.Learn more about Massive Bio's initiative to provide 100,000 cancer patients with free clinical trial pre-screening: https://massivebio.com/oncology-nurse-hour-nsclc. #oncology #nsclc #lungcancer #cancerresearch #clinicaltrials #MET #genomicsComment on this video and subscribe to our channel! Contact Us: Phone: +1 844-627-7246 Email: support@massivebio.com Services: Clinical Trial Matching System The Virtual Tumor Board Visit our website to learn more. https://massivebio.com